150 related articles for article (PubMed ID: 34195092)
1. An Analysis of Cardiac Disorders Associated With Chimeric Antigen Receptor T Cell Therapy in 126 Patients: A Single-Centre Retrospective Study.
Qi K; Yan Z; Cheng H; Chen W; Wang Y; Wang X; Cao J; Zhang H; Sang W; Zhu F; Sun H; Li D; Wu Q; Qiao J; Fu C; Zeng L; Li Z; Zheng J; Xu K
Front Oncol; 2021; 11():691064. PubMed ID: 34195092
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T).
Alvi RM; Frigault MJ; Fradley MG; Jain MD; Mahmood SS; Awadalla M; Lee DH; Zlotoff DA; Zhang L; Drobni ZD; Hassan MZO; Bassily E; Rhea I; Ismail-Khan R; Mulligan CP; Banerji D; Lazaryan A; Shah BD; Rokicki A; Raje N; Chavez JC; Abramson J; Locke FL; Neilan TG
J Am Coll Cardiol; 2019 Dec; 74(25):3099-3108. PubMed ID: 31856966
[TBL] [Abstract][Full Text] [Related]
3. Early Use of Corticosteroids following CAR T-Cell Therapy Correlates with Reduced Risk of High-Grade CRS without Negative Impact on Neurotoxicity or Treatment Outcome.
Lakomy T; Akhoundova D; Nilius H; Kronig MN; Novak U; Daskalakis M; Bacher U; Pabst T
Biomolecules; 2023 Feb; 13(2):. PubMed ID: 36830750
[TBL] [Abstract][Full Text] [Related]
4. Impact of cytokine release syndrome on cardiac function following CD19 CAR-T cell therapy in children and young adults with hematological malignancies.
Shalabi H; Sachdev V; Kulshreshtha A; Cohen JW; Yates B; Rosing DR; Sidenko S; Delbrook C; Mackall C; Wiley B; Lee DW; Shah NN
J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32883871
[TBL] [Abstract][Full Text] [Related]
5. Early Time-to-Tocilizumab after B Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy in Myeloma.
Banerjee R; Marsal J; Huang CY; Lo M; Kambhampati S; Kennedy VE; Arora S; Wolf JL; Martin TG; Wong SW; Shah N
Transplant Cell Ther; 2021 Jun; 27(6):477.e1-477.e7. PubMed ID: 33831353
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular effects associated with chimeric antigen receptor T cell therapy in cancer patients: A meta-analysis.
Chen LR; Li YJ; Zhang Z; Wang P; Zhou T; Qian K; Fan YX; Guo Y; He GH; Shen L
Front Oncol; 2022; 12():924208. PubMed ID: 36439485
[TBL] [Abstract][Full Text] [Related]
7. FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome.
Le RQ; Li L; Yuan W; Shord SS; Nie L; Habtemariam BA; Przepiorka D; Farrell AT; Pazdur R
Oncologist; 2018 Aug; 23(8):943-947. PubMed ID: 29622697
[TBL] [Abstract][Full Text] [Related]
8. Cardiac and inflammatory biomarker differences in adverse cardiac events after chimeric antigen receptor T-Cell therapy: an exploratory study.
Lee DH; Chandrasekhar S; Jain MD; Mhaskar R; Reid K; Lee SB; Corallo S; Hidalgo-Vargas MJ; Kumar A; Chavez J; Shah B; Lazaryan A; Khimani F; Nishihori T; Bachmeier C; Faramand R; Fradley MG; Jeong D; Oliveira GH; Locke FL; Davila ML; Alomar M
Cardiooncology; 2023 Apr; 9(1):18. PubMed ID: 37005652
[TBL] [Abstract][Full Text] [Related]
9. Incidence of MACE in Patients Treated With CAR-T Cell Therapy: A Prospective Study.
Lefebvre B; Kang Y; Vakilpour A; Onoue T; Frey NV; Brahmbhatt P; Huang B; Oladuja K; Koropeckyj-Cox D; Wiredu C; Smith AM; Chittams J; Carver J; Scherrer-Crosbie M
JACC CardioOncol; 2023 Dec; 5(6):747-754. PubMed ID: 38204993
[TBL] [Abstract][Full Text] [Related]
10. Tocilizumab administration in cytokine release syndrome is associated with hypofibrinogenemia after chimeric antigen receptor T-cell therapy for hematologic malignancies.
Perl M; Herfeld K; Harrer DC; Höpting M; Schweiger M; Sterz U; Knödler L; Heimerl S; Hansmann L; Herr W; Poeck H; Wolff D; Edinger M; Hart C; Fante MA
Haematologica; 2024 Mar; ():. PubMed ID: 38546698
[TBL] [Abstract][Full Text] [Related]
11. Prophylactic Tocilizumab Prior to Anti-CD19 CAR-T Cell Therapy for Non-Hodgkin Lymphoma.
Caimi PF; Pacheco Sanchez G; Sharma A; Otegbeye F; Ahmed N; Rojas P; Patel S; Kleinsorge Block S; Schiavone J; Zamborsky K; Boughan K; Hillian A; Reese-Koc J; Maschan M; Dropulic B; Sekaly RP; de Lima M
Front Immunol; 2021; 12():745320. PubMed ID: 34712233
[TBL] [Abstract][Full Text] [Related]
12. Cardiotoxicity of T-Cell Antineoplastic Therapies:
Ganatra S; Dani SS; Yang EH; Zaha VG; Nohria A
JACC CardioOncol; 2022 Dec; 4(5):616-623. PubMed ID: 36636447
[TBL] [Abstract][Full Text] [Related]
13. Treatment-Related Adverse Events of Chimeric Antigen Receptor T-Cell (CAR T) in Clinical Trials: A Systematic Review and Meta-Analysis.
Lei W; Xie M; Jiang Q; Xu N; Li P; Liang A; Young KH; Qian W
Cancers (Basel); 2021 Aug; 13(15):. PubMed ID: 34359816
[TBL] [Abstract][Full Text] [Related]
14. Characteristics and Risk Factors of Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Treatment.
Yan Z; Zhang H; Cao J; Zhang C; Liu H; Huang H; Cheng H; Qiao J; Wang Y; Wang Y; Gao L; Shi M; Sang W; Zhu F; Li D; Sun H; Wu Q; Qi Y; Li H; Wang X; Li Z; Liu H; Zheng J; Qian W; Zhang X; Xu K
Front Immunol; 2021; 12():611366. PubMed ID: 33708205
[TBL] [Abstract][Full Text] [Related]
15. Case Report: Cardiac Tamponade in Association With Cytokine Release Syndrome Following CAR-T Cell Therapy.
Moriyama S; Fukata M; Yokoyama T; Ueno S; Nunomura T; Mori Y; Kato K; Miyamoto T; Akashi K
Front Cardiovasc Med; 2022; 9():848091. PubMed ID: 35387436
[TBL] [Abstract][Full Text] [Related]
16. Imaging-based Toxicity and Response Pattern Assessment Following CAR T-Cell Therapy.
Smith DA; Kikano E; Tirumani SH; de Lima M; Caimi P; Ramaiya NH
Radiology; 2022 Feb; 302(2):438-445. PubMed ID: 34751616
[TBL] [Abstract][Full Text] [Related]
17. Glycyrrhizin for treatment of CRS caused by CAR T-cell therapy: A pharmacological perspective.
Qi X; Li J; Luo P
Front Pharmacol; 2023; 14():1134174. PubMed ID: 36923358
[TBL] [Abstract][Full Text] [Related]
18. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
Front Immunol; 2020; 11():564099. PubMed ID: 33329526
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular disease and chimeric antigen receptor cellular therapy.
Rao A; Stewart A; Eljalby M; Ramakrishnan P; Anderson LD; Awan FT; Chandra A; Vallabhaneni S; Zhang K; Zaha VG
Front Cardiovasc Med; 2022; 9():932347. PubMed ID: 36211558
[TBL] [Abstract][Full Text] [Related]
20. Toci or not toci: innovations in the diagnosis, prevention, and early management of cytokine release syndrome.
Banerjee R; Fakhri B; Shah N
Leuk Lymphoma; 2021 Nov; 62(11):2600-2611. PubMed ID: 34151714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
